羟氯喹在 2019 年冠状病毒病患者中的应用：动力学方面仍有哪些未知。
Hydroxychloroquine in Coronavirus Disease 2019 Patients: What Still Needs to Be Known About the Kinetics.
机构信息
Service des Maladies Infectieuses et Tropicales, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France.
Service de Réanimation - Rangueil, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France.
出版信息
Clin Infect Dis. 2020 Dec 31;71(11):2962-2964. doi: 10.1093/cid/ciaa558.
Abstract
Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 days, and concentrations were compared with simulated kinetic profiles. Hydroxychloroquine exposure is low and cannot be predicted by other populations.
摘要
不同剂量的羟氯喹被用于治疗 2019 冠状病毒病（COVID-19）患者，但针对该人群的药代动力学信息尚未可知。从 57 名 COVID-19 患者中采集了 101 份血样，持续 7 天，并与模拟的动力学曲线进行了比较。羟氯喹的暴露水平较低，无法通过其他人群进行预测。
相似文献
1
Hydroxychloroquine in Coronavirus Disease 2019 Patients: What Still Needs to Be Known About the Kinetics.羟氯喹在 2019 年冠状病毒病患者中的应用：动力学方面仍有哪些未知。
Clin Infect Dis. 2020 Dec 31;71(11):2962-2964. doi: 10.1093/cid/ciaa558.
2
COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.新型冠状病毒肺炎疫情：氯喹和羟氯喹潜在作用的叙事性综述。
Pain Physician. 2020 Aug;23(4S):S351-S366.
3
A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics.一项实用随机对照试验报告称羟氯喹对 2019 年冠状病毒病病毒动力学无效。
Nat Commun. 2020 Oct 20;11(1):5284. doi: 10.1038/s41467-020-19056-6.
4
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.羟氯喹作为暴露后预防严重急性呼吸综合征冠状病毒 2 感染的药物：一项随机试验。
Ann Intern Med. 2021 Mar;174(3):344-352. doi: 10.7326/M20-6519. Epub 2020 Dec 8.
5
Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19.羟氯喹在 COVID-19 重症患者肺部的药代动力学。
Int J Antimicrob Agents. 2021 Feb;57(2):106247. doi: 10.1016/j.ijantimicag.2020.106247. Epub 2020 Nov 28.
6
Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019.将羟氯喹的体外抗病毒活性与体内浓度相关联，以预测其抗病毒效果：这是治疗 2019 年冠状病毒病患者的关键步骤。
Clin Infect Dis. 2020 Dec 15;71(12):3232-3236. doi: 10.1093/cid/ciaa623.
7
Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19.硫酸羟氯喹治疗 COVID-19 的临床药理学综述。
Curr Drug Metab. 2020;21(6):427-435. doi: 10.2174/1389200221666200610172929.
8
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.一项评估法匹拉韦和羟氯喹联合治疗中重度 COVID-19 住院成人的疗效和安全性的随机对照研究：研究方案的结构化总结。
Trials. 2020 Oct 31;21(1):904. doi: 10.1186/s13063-020-04825-x.
9
Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.氯喹和羟氯喹在2019冠状病毒病中的应用：对医疗保健专业人员的实践启示
J Coll Physicians Surg Pak. 2020 Oct;30(10):124-128. doi: 10.29271/jcpsp.2020.supp2.124.
10
Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned.羟氯喹与 COVID-19：风湿病专家对经验教训的看法。
Curr Allergy Asthma Rep. 2021 Jan 21;21(1):5. doi: 10.1007/s11882-020-00983-9.
引用本文的文献
1
Hydroxychloroquine serum concentration in coronavirus disease 2019 (COVID-19) patients: a retrospective study.2019冠状病毒病（COVID-19）患者的羟氯喹血清浓度：一项回顾性研究。
Forensic Sci Res. 2021 Aug 19;6(3):215-217. doi: 10.1080/20961790.2021.1936896. eCollection 2021.
2
Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.羟氯喹在新冠肺炎患者中的群体药代动力学：对剂量优化的启示。
Eur J Drug Metab Pharmacokinet. 2020 Dec;45(6):703-713. doi: 10.1007/s13318-020-00648-y.
3
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants.低剂量羟氯喹治疗对 COVID-19 住院患者死亡率的影响：一项全国性观察研究，纳入 8075 名参与者。
Int J Antimicrob Agents. 2020 Oct;56(4):106144. doi: 10.1016/j.ijantimicag.2020.106144. Epub 2020 Aug 24.
4
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.对 COVID-19 感染新治疗领域的药代动力学（PK）和药代动力学-药效学（PK-PD）研究的关注。
Antiviral Res. 2020 Sep;181:104866. doi: 10.1016/j.antiviral.2020.104866. Epub 2020 Jul 10.
5
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.SARS-CoV-2 全身炎症反应对洛匹那韦和羟氯喹血浆浓度的影响。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01177-20.
6
Dose Optimization of Hydroxychloroquine for Coronavirus Infection 2019: Do Blood Concentrations Matter?2019年冠状病毒感染中羟氯喹的剂量优化：血药浓度重要吗？
Clin Infect Dis. 2020 Dec 31;71(11):2965-2967. doi: 10.1093/cid/ciaa691.
Zotero 插件